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ARTICLE
Loss-of-function and missense variants in NSD2 cause
decreased methylation activity and are associated with
a distinct developmental phenotype
Paolo Zanoni 1,31✉, Katharina Steindl1,31, Deepanwita Sengupta2,31, Pascal Joset1, Angela Bahr1, Heinrich Sticht3,
Mariarosaria Lang-Muritano4,5, Conny M. A. van Ravenswaaij-Arts6, Marwan Shinawi7, Marisa Andrews7, Tania Attie-Bitach8,9,
Isabelle Maystadt10,11, Newell Belnap12,13, Valerie Benoit10,14, Geoffroy Delplancq15,16, Bert B. A. de Vries17, Sarah Grotto18,
Didier Lacombe19, Austin Larson20, Jeroen Mourmans21, Katrin Õunap22,23, Giulia Petrilli8, Rolph Pfundt17, Keri Ramsey12,13,
Lot Snijders Blok17, Vassilis Tsatsaris18, Antonio Vitobello24, Laurence Faivre25, Patricia G. Wheeler26, Marijke R. Wevers17,
Monica Wojcik27,28, Markus Zweier1, Or Gozani2,32 and Anita Rauch1,29,30,32✉
PURPOSE: Despite a few recent reports of patients harboring truncating variants in NSD2, a gene considered critical for the
Wolf–Hirschhorn syndrome (WHS) phenotype, the clinical spectrum associated with NSD2 pathogenic variants remains poorly
understood.
METHODS: We collected a comprehensive series of 18 unpublished patients carrying heterozygous missense, elongating, or
truncating NSD2 variants; compared their clinical data to the typical WHS phenotype after pooling them with ten previously
described patients; and assessed the underlying molecular mechanism by structural modeling and measuring methylation activity
in vitro.
RESULTS: The core NSD2-associated phenotype includes mostly mild developmental delay, prenatal-onset growth retardation,
low body mass index, and characteristic facial features distinct from WHS. Patients carrying missense variants were significantly
taller and had more frequent behavioral/psychological issues compared with those harboring truncating variants. Structural in
silico modeling suggested interference with NSD2’s folding and function for all missense variants in known structures. In vitro
testing showed reduced methylation activity and failure to reconstitute H3K36me2 in NSD2 knockout cells for most missense
variants.
CONCLUSION: NSD2 loss-of-function variants lead to a distinct, rather mild phenotype partially overlapping with WHS. To avoid
confusion for patients, NSD2 deficiency may be named Rauch–Steindl syndrome after the delineators of this phenotype.
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INTRODUCTION
Wolf–Hirschhorn syndrome (WHS, also known as 4p-syndrome,
OMIM 194190) caused by partial deletions of the short arm of
chromosome 4 is one of the first microscopically recognized
structural chromosomal disorders, and was named after Ulrich Wolf
(Freiburg, Germany) and Kurt Hirschhorn (New York, NY, USA), who
first described it in 1965.1,2 Hallmarks of the syndrome are prenatal-
onset growth deficiency, microcephaly, intellectual disability (ID),
epilepsy, muscular hypotonia and hypotrophy, facial clefts, con-
genital heart defects and other malformations, as well as a very
characteristic craniofacial gestalt, often described as resembling
a Greek helmet.3 With the advent of molecular cytogenetics a
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number of patients with smaller deletions encompassing 4p16.3
were identified, with deletions below 3.5Mb found to be associated
with a milder phenotype without major malformations.3 Following
an observation by Dian Donnai (Manchester, UK)4 individuals
described as having Pitt–Rogers–Danks syndrome were shown to
also harbor 4p16.3 microdeletions sizing at least 3.7 Mb5 and, as
pointed out by Agatino Battaglia (Pisa, Italy) and John C. Carey (Salt
Lake City, UT, USA), are actually clinically indistinguishable from
WHS.6 Further refinement of the WHS critical region hinted at NSD2
(also named WHSC1 or MMSET, OMIM *602952) as the gene possibly
responsible for part of the manifestations of WHS, including growth
retardation, ID, and possibly susceptibility to infections.7–10 This
hypothesis was supported by a role for NSD2 in neuronal
development as well as in the regulation of cellular proliferation
in vitro.11–13 A total of eight truncating, two splicing, and six
missense variants were listed among many others in sequencing
studies of patient cohorts with neurodevelopmental disorders,
growth abnormality, or congenital heart defects without deep
phenotyping information (Table S1).
Recently, eight individual patients with developmental delay (DD)
and growth retardation carrying truncating or protein-elongating
variants in NSD2 have been described,14–18 with phenotypes that
partially overlap with those of individuals carrying very small
chromosomal deletions encompassing NSD2.8–10
However, the lack of larger systematic patient series and
functional validation is hampering the understanding of the
phenotype associated with NSD2 constitutional variants. Here
we report 18 additional deep-phenotyped individuals carrying
heterozygous (likely) pathogenic NSD2 variants, including a
prenatal and two familial cases, together with in silico and
in vitro data providing insight into the underlying pathome-
chanism and genotype–phenotype correlations.
MATERIALS AND METHODS
The 18 previously undescribed patients with pathogenic NSD2 variants
reported in this study were identified by research or diagnostic exome or
Mendeliome sequencing in various laboratories and collected via
GeneMatcher (see Web Resources). When no developmental testing was
performed, the degree of ID was estimated using the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) severity levels
for ID (see Web Resources). Standard deviation scores for growth
parameters were calculated based on the data sets provided by the Swiss
Society of Pediatrics, which combine World Health Organization, Swiss, and
German population data (see Web Resources). The facial overlay Fig. 4b
was obtained using the Face2Gene RESEARCH application (FDNA Inc.,
Boston, MA, USA) taking one frontal photo for each patient at the youngest
available age.
NSD2 variant nomenclature refers to the NM_133330.2 transcript and
pathogenicity classification is based on the American College of Medical
Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP)
guidelines.19 Structural analysis of NSD2 variants was performed using
SwissModel, RasMol, and Smart (see Web Resources). While the experi-
mental crystal structure of the NSD2 N-methyltransferase domain was
available (Protein Data Bank, PDB: 5LSU), the PHD and PWWP domains
were modeled using the homologous domains from TRIM24 (PDB: 4ZQL)
and NSD3 (PDB code: 2DAQ), respectively.
GST fusion proteins were obtained as described in the Supplementary
methods. In vitro methylation assays were performed as described in
Mazur et al.20 and the Supplemental methods using reagents listed in
Table S2.
The data in Fig. 2n, p, r, t are represented as mean ± SD of two
independent biological replicates; statistical significance was tested by
one-way analysis of variance (ANOVA) followed by two-tailed Dunnett’s
test without adjusting for multiple testing. The data in Fig. 3c–e are
represented as mean ± SD. Groups in Fig. 3e were compared by
homoscedastic two-tailed Student’s t-test after testing for equal variance
by F-test.
The graphs in Figs. 2n, p, r, t and 3a–f were generated using GraphPad
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Fig. 1 Localization of the NSD2 variants. The diagram shows the structure of the NSD2 gene (above) and protein (below, isoform 1, encoded
by the NM_133330.2 transcript) together with the variants discussed in this study as well as variants that have previously been reported in
large sequencing studies. The variants carried by the 18 additional individuals described in this study are in bold. Observed germline variants
absent in the HGMD database are underlined. † Shared by more than one patient; # variant of uncertain significance (VUS)/likely benign. The
observed pathogenic missense variants we found map to three distinct domains of NSD2: a PHD zinc-finger domain (residues 831–875), a
PWWP domain (residues 880–942), and the catalytic methyltransferase domain (residues 1011–1203; composed of three subdomains, namely
an AWS, a SET, and a post-SET domain). The color coding of the variants and protein domains is reported in the legend. AWS Associated With
SET domain (IPR006560), GOF gain of function, HMG high mobility group box domain (IPR009071), LOF loss of function, MTD catalytic
methyltransferase domain, composed by the AWS, SET and a post-SET domain, PHD zinc-finger domain, Plant-HomeoDomain type
(IPR001965), PWWP proline–tryptophan–tryptophan–proline domain (IPR000313), SET Su(Var)3-9, enhancer-of-zeste, trithorax domain
(IPR001214). Domains were annotated according to the Uniprot databank (see Web Resources).
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All statistical analyses were performed with GraphPad Prism, except for F-
and t-tests, which were performed using Microsoft© Excel.
RESULTS
We describe 18 patients, 16 of whom unrelated, carrying ultrarare
(absent in gnomAD) pathogenic or likely pathogenic NSD2 variants
(Table S3). Of these, 6 carried 5 different missense variants while 12
carried 10 different truncating variants. Nine of the truncating and
four of the missense variants were not reported previously (Fig. 1).
Variant inheritance could not be determined in 4/18 cases, and was
confirmed parental in 3/18 cases and de novo in 11/18 cases.
NSD2 is the principal enzyme that dimethylates histone H3
at lysine 36 (H3K36me2)11 in most cell types and tissues.21
H3K36me2 is an evolutionarily conserved histone modification
linked to transcriptional activation. The (likely) pathogenic
missense variants we found map to three distinct domains of
NSD2. The Cys869Tyr (patient 1-I) substitution disrupts zinc
binding within a PHD finger domain (residues 831-875) and
hence induces improper folding and loss of function for this
domain. Although the function of the NSD2 PHD domain is
unknown, these domains are virtually always found on chromatin-
associated proteins and may function as epigenetic reader
domains (Fig. 2a, b). The Pro895Leu variant (patients 7-I and 7-II)
is located in the core of one of NSD2’s PWWP domains (Fig. 2c),
another motif that generally functions as an epigenetic reader.22
The leucine substitution at Pro895 is predicted to destabilize the
domain through steric clashes with the adjacent Trp885 (Fig. 2d).
All remaining missense variants are located within the
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located in a loop of the methyltransferase domain that exhibits
high local mobility or is entirely missing in the isolated NSD2
crystal structure. This hampers reliable modeling but suggests that
this region is flexible and might become stabilized upon
protein–protein interactions, such as binding to the nucleosome
substrate. Ser1137 is located in the domain’s core (Fig. 2e) and
substitution to phenylalanine (p.Ser1137Phe, patient 10-I) is
predicted to result in steric clashes with the adjacent Leu1163
residue (Fig. 2f), leading to domain destabilization. Glu1091 forms
a salt bridge to Arg1160 in the wild-type structure (Fig. 2g), which
is disrupted due to the charge inversion in the Glu1091Lys variant
(patient 5-I, Fig. 2h). In addition, the longer Lys1091 sidechain
forms steric clashes with Arg1160, which are expected to
additionally destabilize the methyltransferase domain. To corro-
borate our in silico and in vitro data, we also tested previously
functionally characterized substitutions within the methyltransfer-
ase domain, namely Glu1099Lys, Tyr1092Ala, and Tyr1179Ala.
Glu1099Lys is a recurrent variant found somatically in multiple
cancer types including childhood leukemia and enhances
methylation activity to alter global histone methylation.23
Molecular modeling23 suggested that the positively charged
lysine may disrupt the favorable histone–enzyme interactions
leading to a gain of function. Tyr1092Ala and Tyr1179Ala were not
previously identified in patients but had been shown to abrogate
catalytic activity based on homology to other SET domain protein
lysine methyltransferase enzymes.11 Tyr1092 forms tight hydro-
phobic interactions with Leu1120 in the protein core (Fig. 2I). Due
to the shorter sidechain, these interactions are lost in the Ala1092
variant (Fig. 2j) thereby predicted to destabilize the protein
domain. Modeling of the Tyr1179Ala variant reveals that Tyr1179
forms direct interactions with the bound methyl donor S-
adenosylmethionine (SAM, Fig. 2k). These interactions are lost in
the Tyr1179Ala mutant (Fig. 2l), resulting in a predicted strong
reduction of cofactor binding and hence loss of enzymatic activity.
Based on these data, we postulated that one functional
consequence of the NSD2 missense variants identified in patients
with developmental disorders might be disruption of NSD2’s
ability to generate H3K36me2.
To test this hypothesis, we determined H3K36me2 levels in
HEK293T cells transiently transfected with NSD2 wild-type or
derivatives harboring the various variants (Fig. 2m, n). Consistent
with previous work,11,22 overexpression of wild-type NSD2 and a
cancer-related NSD2 gain-of-function mutant (Glu1099Lys
[E1099K])23 caused a global increase in H3K36me2. Contrarily,
the NSD2 derivatives carrying variants observed in patients, apart
from Cys869Tyr [C869Y] (patient 1-I) and Glu1091Lys [E1091K]
(patient 5-I), significantly reduced the levels of H3K36me2 (Fig. 2m;
quantitation in Fig. 2n). In particular, Ser1137Phe [S1137F] (patient
10-I) largely behaved like the negative control and the known
NSD2 catalytic mutant Tyr1179Ala [Y1179A] (Fig. 2m, n). Given that
Ser1137Phe (patient 10-I) is located within the SET domain, the
data suggest that this variant causes direct impairment of NSD2’s
catalytic activity. To test this hypothesis, in vitro methylation
assays were performed using a minimal domain of NSD2 that
retains enzymatic activity11 and recombinant nucleosomes as
substrates. As shown in Fig. 2o and q (quantitation in Fig. 2p and r,
respectively), Ser1137Phe (patient 10-I) abrogates NSD2’s ability to
methylate nucleosomes in vitro similarly to the previously
characterized catalytic mutant Tyr1179Ala [Y1179A]), while
Glu1091Lys (patient 5-I) and Lys1019Arg [K1019R] (patient 12-I)
showed a modest reduction in methylation of nucleosomes
(Fig. 2o–r). Cys869Tyr (patient 1-I) and Pro895Leu (patients 7-I and
7-II) lie outside of the minimal catalytic domain and thus could not
be tested in this assay. Next, we used the CRISPR/Cas9 system to
generate NSD2-depleted HT1080 cells, which leads to depletion of
global H3K36me2, and then complemented these cells with
CRISPR-resistant wild-type NSD2 or the DD-associated NSD2
variants to test their role in reconstituting physiologic levels of
H3K36me2. In contrast to complementation with wild-type NSD2
and gain-of function NSD2-Glu1099Lys, cells complemented with
the DD-associated NSD2 variants were partially to largely
compromised in their ability to rescue physiologic H3K36me2
levels, with Glu1091Lys (patient 5-I) being the only variant that did
not reach statistical significance (Fig. 2s, t). The Ser1137Phe variant
(patient 10-I) completely failed to rescue, indicating that it
essentially abolishes enzymatic activity. Overall, these data are
consistent with all variants except Cys869Tyr (patient 1-I)
compromising to varying degrees the ability of NSD2 to generate
H3K36me2, a key epigenetic modification.
The main clinical features of the NSD2 cohort consisting of 18
individuals described here and 10 previously published individuals
(8 carrying truncating or protein-elongating variants14–18 and 2
carrying a microdeletion that encompasses the NSD2 gene only10)
are summarized in Fig. 3a and compared to patients with WHS due
to 4p deletions of different sizes reported in a large series of 166
affected individuals3 (Fig. 3b). Postmortem pathological findings for
case 16-I, a male fetus whose pregnancy was terminated at the 27th
week of gestation, are shown in Figure S1. Detailed clinical
descriptions are provided in the supplement.
In the NSD2 cohort, the average age at last visit (±SD) was 9.3
(±10.3) years and the male to female ratio was 18:10 (male 64%,
female 36%). Seventy-five percent of the NSD2 variants were de
novo, 14% were inherited from an affected parent, while in 11% of
the cases, the inheritance pattern could not be established.
Fig. 2 Structural and functional effect of two synthetic and four naturally occurring pathogenic NSD2 missense variants. (a) Wild-type
(WT) Cys869 is one of four cysteines that tetrahedrally coordinate a zinc ion (Cys846, Cys849, Cys869, Cys872 are shown in stick presentation;
the Zn2+ is depicted as a brown ball). (b) The variant Tyr869 adopts a different sidechain orientation resulting in a loss of the zinc ion (marked
by a red arrow). (c) WT Pro895 is located in spatial proximity of Trp885 (cyan). (d) The longer Leu895 sidechain present in the variant results in
steric clashes with Trp885 (marked by a red dotted circle). (e) WT Ser1137 is located in spatial proximity of Leu1163 (cyan). (f) The bulkier
Phe1173 sidechain present in the variant results in steric clashes with Leu1163 (marked by a red dotted circle). (g) WT Glu1091 forms a salt
bridge to Arg1160 (green arrow), which is disrupted in the (h) Lys1091 variant and steric clashes are formed instead (red arrow). (i) WT Tyr1092
forms tight van der Waals interactions with Leu1120 (cyan), which are lost in the synthetic (j) Ala1092 variant11 (the site of altered interactions
is denoted by a red arrow). (k) WT Tyr1179 forms stabilizing interactions to S-adenosylmethionine (SAM, cyan). (l) The shorter sidechain in the
synthetic Ala1179 variant11 results in a loss of interactions with the SAM cofactor (red arrow), which is expected to result in a drastic loss of
enzymatic activity. (m) Western analysis with the indicated antibodies of whole-cell extracts (WCEs) from 293 T cells overexpressing vector
control, full-length WT NSD2, or NSD2 mutants as indicated. Histone H3 is shown as a loading control. (n) Quantification of western blot data
in (m). (o) In vitro methylation assay with recombinant WT NSD2 or mutant NSD2 derivatives as indicated on recombinant nucleosomes (rNuc)
as substrates. Top panel, 3H-SAM is the methyl donor and methylation is visualized by autoradiography and indicated as 3H-H3. Bottom panel,
Coomassie stain of proteins in the reaction. (p) Quantification of all detectable bands in the autoradiography in (o). (q) Western analysis with
the indicated antibodies of in vitro methylation assay with nonradiolabeled SAM. (r) Quantification of all detectable bands in the western blot
data in (q). (s) Western analysis with the indicated antibodies of WCEs from WT or NSD2 deficient HT1080 cells complemented with CRISPR-
resistant NSD2 (WT or mutants), or control as indicated. Histone H3 and tubulin are shown as loading controls. (t) Quantification of western
blots in (s). The data in (n, p, r, t) are represented as mean ± SD of two independent experiments. *p < 0.05 based on a one-way analysis of
variance (ANOVA) followed by two-tailed Dunnett’s test.
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Patients with (likely) pathogenic NSD2 variants shared a similar
facial gestalt characterized by a triangular face, broad forehead,
high anterior hairline, deeply set eyes, large palpebral fissures,
broad arched and laterally sparse eyebrows, periorbital hyperpig-
mentation, full cheeks, a thin and elevated nasal bridge, smooth
short philtrum, prominent cupid bow, thick everted lower lip
vermilion, and/or protruding ears (Fig. 4a, b). Noticeably, the facial
appearance evolved over time, with older patients developing
deeper infraorbital creases. Family 6 comprised a total of 7
clinically similarly affected individuals, with molecular confirma-
tion available for four of them, and represents to date the largest
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phenotype of the NSD2 cohort (>50% of patients) is characterized
by DD, intrauterine growth retardation and low birth weight,
feeding difficulties, failure to thrive, height and head circumfer-
ence below the 5th centile (<−1.65 SDS), speech delay, and
muscular hypotonia. Although these manifestations are present in
WHS as well, the majority of the individuals in the NSD2 cohort
lack many of the most common manifestations of WHS such as
seizures,3 orofacial clefts, and coloboma, as well as genital, cardiac,
and renal malformations and display a distinct facial phenotype
that lacks the classical “Greek helmet” aspect. Furthermore, the
severity of the ID in the NSD2 cohort was milder compared with
patients carrying the most common 4p deletions (between 5 and
18Mb), who are severely affected in 76% of the cases.3 While
individuals 1-I, 13-I, and 14-I harboring the NSD2 Cys869Tyr,
p.Cys1183Valfs*146, and p.Arg600* variants respectively, either
had an IQ in the lower-normal range (78–81 and 89, respectively)
or presented with learning difficulties, individuals old enough for
evaluation commonly showed mild ID, with only three individuals
presenting with severe ID. The latter carried truncating variants
(3-I c.3223_3226dup p.Gly1076Valfs*16; 4-1c.1588_1589dupAA
p.Ile532Glyfs*67; Bernardini et al., patient 3, exon 1–20 deletion),
which may not be held responsible for the severe ID. Both siblings
described as patients 2 and 3 in Bernardini et al. carry in fact the
same exon 1–20 deletion, with one sibling showing mild ID, while
the other had autism and severe ID.10
Behavioral and psychological issues as well as autistic features
were observed in 44% and 33%, respectively, with the most
frequently reported manifestations being anxiety (15%), hyper-
activity (22%), and aggressiveness (11%). Individual 1-I had
suicidal ideations related to his poor academic performance at
the age of 11 years. Of note, all the individuals carrying missense
variants presented with behavioral and psychological issues
(Fig. 3a), compared to 29% of patients with truncating variants
or deletions (p value = 0.0031 by two-tailed Fisher’s exact test).
Growth parameters at birth were largely below the norm
(Fig. 3c). Feeding difficulties were described in 52% of the affected
individuals and may at least in part contribute to the failure to
thrive. Short stature and growth retardation persisted later in life
(Fig. 3d). Delayed bone age was detected in 6 individuals (22%).
Length and occipitofrontal circumference (OFC) at birth as well as
all growth parameters at last visit were normally distributed
according to a D’Agostino–Pearson omnibus normality test, while
birth weight was skewed toward lower values (p= 0.0002).
Notably, heterozygotes for missense variants were significantly
taller than patients carrying truncating variants as well as small
deletions encompassing NSD2 (p= 0.03 by homoscedastic t-test
after checking for comparable variance by F-test; Fig. 3e) and none
of them fell below the 5th centile for height at last visit. Weight
and OFC at last visit were also higher in patients carrying missense
variants, although this difference was not statistically significant
(p= 0.27 and 0.17, respectively). Finally, a linear regression
analysis showed that older patients had significantly higher body
mass index (BMI) values (r² = 0.1786, p= 0.0396; Fig. 3f).
Gastrointestinal abnormalities were also quite common (43%),
with constipation representing the most frequent manifestation
(26%). Ophthalmological abnormalities were observed in 29% of
patients and mostly included mild refraction defects and
strabismus, while no individual presented with coloboma, which
is considered a recurrent feature in WHS (see Fig. 3b). One
exception is represented by individual 3-I, who presented with
bilateral keratoconus, retinitis pigmentosa, and optic atrophy
and received a corneal transplant at the age of 32. Reanalysis of
her exome data revealed three rare variants of unknown
significance in RHO, KRT3, and UNC45B (Table S3), which were,
however, maternally inherited and also present in her healthy
sister. Skeletal and limb abnormalities were reported in 39% of
the cases. Individual 12-I presented with a craniosynostosis that
was surgically corrected at the age of 6 months, which may be
explained by the patient’s additional de novo heterozygous
AGO2 variant (Table S3). Also, of note, individual 7-II presented
with 11 ossified ribs and 6 non-rib-bearing lumbar vertebrae.
Dental abnormalities were also quite frequent (32%). Brain and
spinal cord malformations were present in 5 individuals (18%)
and were mostly of minor importance except for individual 16-I,
who presented with vermis hypoplasia. Less frequent manifesta-
tions among patients carrying NSD2 pathogenic variants
included a history of aspiration, cardiac and renal anomalies,
neonatal jaundice, sleep disturbances, hearing loss, genital
abnormalities, and orofacial clefts (Table S3). Immunological
abnormalities as well as recurrent infections, which represent a
common morbidity and mortality cause in WHS,24 were
infrequent in the NSD2 cohort, where patient 5-I presented with
latex allergy, patient 11-I with low IgA and IgG3 levels, and
patients 2-I, 11-I and Derar-1 with recurrent respiratory infec-
tions. Seizures, which are common in WHS (Fig. 3b), were
reported only in individual 10-I, while individual 15-I presented
subclinical electroencephalogram (EEG) abnormalities at the age
of 4 4/12 years. Endocrinological abnormalities seem not to be
part of the phenotypic spectrum, with only individual 5-I
presenting limited signs of precocious puberty at 15 months of
age, which were nonprogressive and were associated with a
normal endocrine evaluation. Likewise, metabolic abnormalities
were only observed in individual 2-I.
DISCUSSION
In this work we describe a large series of patients carrying
pathogenic variants in NSD2, thus allowing delineation of the
associated manifestations, which include prenatal-onset failure to
thrive with all body measurements below the mean and low BMI,
mild DD and muscular hypotonia, and a distinct facial gestalt.
Furthermore, we provide in silico and in vitro mechanistic data
showing loss of histone methylation activity as a common feature
of NSD2 deficiency.
The phenotype observed in the NSD2 cohort is consistent with
many of the known functions of NSD2. First, NSD2 has long been
known to regulate embryonic development and body growth,
Fig. 3 Phenotypic features and growth parameters of the individuals carrying NSD2 pathogenic variants and comparison with
Wolf–Hirschhorn syndrome (WHS). The diagram in (a) summarizes the phenotypic features of the individuals described in this study (18
additional patients together with 10 previously reported individuals) based on the type of NSD2 variant carried. In (b) all individuals are
compared with WHS patients, subdivided according to the size of the 4p deletion carried, as reported in Zollino et al.3 Data in (a) and (b) are
expressed as percentages. Growth parameters at birth (c; included the parameters at termination of pregnancy for individual 16-I) and at last
visit (d) are reported. The average measures for all combined individuals standard deviation score (SDS [SD]) were length (L): -2.3 (1.5); weight
(W): -2.0(1.0); occipitofrontal circumference (OFC): -1.1(1.7); gestational weeks (GW): 38.5(3.8) at birth and height (H): -1.7(1.3); W: -1.7(1.5); OFC:
-2.4(1.8); body mass index (BMI): -1(1.5) at last visit. (e) Comparison of the growth parameters at last visit for patients carrying missense variants
(black) compared with patients carrying other variants as well as deletions encompassing NSD2 (red). *p value < 0.05 as tested by two-tailed
Student’s t-test. The data in (c–e) are expressed as SDS based on the respective growth charts. Lines and whiskers represent mean ± SD.
(f) Linear correlation analysis between age and BMI and last visit. ASD DD/ID developmental delay/intellectual disability, IUGR intrauterine
growth restriction, SC spinal cord, SGA small for gestational age.
P. Zanoni et al.
6
Genetics in Medicine _#####################_
with heterozygous Nsd2 constitutive knockout mice growing at a
much slower rate compared with wild-type littermates, homo-
zygous knockout mice dying in the first days of life,25 and
common variants showing strong (p= 10−24) association with
height in genome-wide association study (GWAS).26 Recently
NSD2 was shown to regulate adipose tissue development in mice
by controlling the activity of the master adipogenic transcription
factor peroxisome proliferator-activated receptor-γ (PPARγ).27
Interestingly, in this work mice overexpressing the mutant histone
protein H3.3K36M, an NSD2 inhibitor, resisted white adipose tissue
expansion in response to a high-fat diet. These findings support
the idea that the low BMI observed in the NSD2 cohort may be
due to the inability of body fat to expand in response to feeding
rather than a consequence of the neonatal feeding difficulties
that, although observed in multiple affected individuals, disappear
later in life. Furthermore, NSD2 has been shown to play a key role
in promoting adipogenesis and myogenesis in precursor cells, as
well as thermogenesis in brown adipose tissue and insulin
sensitivity in white adipose tissue.27 In pancreatic β-cell lines
in vitro NSD2 has also been shown to promote proliferation and to
a





M ?/?M ?/?M ?/?M +/-
M +/-
M +/-
13-I; 6y 14-I; 7m 14-I; 3y 10m 14-I; 6y 14-I; 7y 14-I; 8y 10m
15-I; 1y 4m 15-I; 2y 3m 15-I; 3y 1m
5-I; 5y0m1-I; 14y1-I; 11y 2-I; 2y2m1-I; 18y 3-I; 50y
Fig. 4 Clinical data. (a) Facial features of the affected individuals reported in this study. The age in years (y) and months (m) is reported beside
each patient ID. (b) Combined facial gestalt obtained by combining frontal photos using the Face2Gene online research tool (see Materials
and Methods and Web Resources). Photos from 12 different patients, including those depicted in (a), were used for this purpose. (c) Family
tree of family number 6 in this study. M+/−/?= presence (+), absence (−), or unknown status (?) for the p.Asp1158Glyfs*11 variant in each
NSD2 allele. Clinically affected individuals are shown as full symbols.
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regulate insulin secretion.28 However, since diabetes has not been
reported as a recurrent feature neither in our cohort nor in
patients with WHS we assume that in humans, glycemic control
may be maintained despite impaired NSD2 function.
Likewise, some other known or supposed functions of NSD2 did
not result in a recurrent phenotype in our cohort. NSD2 has been
suggested to contribute to the immune defects typical of WHS by
regulating the hematopoietic process at multiple stages as well as
B-29 and T-cell30 differentiation. Nevertheless, only a minority of
the patients in this series presented with recurrent infections. Also,
while heterozygous Nsd2 deficient mice present with heart
defects25 and de novo variants in NSD2 were shown to associate
with congenital heart malformations,31 cardiac anomalies were
present only in a minority of the individuals in this series, and, with
the exception of individual 16-I, were of minor clinical importance.
The low prevalence of epilepsy in this cohort is compatible with
the assumption that other genes such as LETM1 are responsible
for seizures in WHS.32,33
While heterozygotes for missense variants were on average
significantly taller, the overall clinical severity correlated only
loosely with the measured alteration in NSD2 enzymatic
function. Furthermore, for the Cys869Tyr (patient 1-I) variant,
which can be categorized as likely pathogenic based on the
current ACMG/AMP recommendations,19 we did not detect
significant loss of methylation activity in our in vitro assays.
These data suggest that in addition to H3K36 dimethylation,
other functions of NSD2 such as its genomic localization, and
likely other potential genetic differences among the patients,
contribute to the pathogenesis of the complex phenotypes
described here. Moreover, as the missense variants that we
tested did not display any obvious stability issue upon
overexpression, dominant negative effects cannot be excluded.
Finally, second hits or blending phenotypes with additional
variants in other (known or unknown) genes associated with the
clinical phenotypes described in this study could contribute to
the observed clinical variability.
Patients 11-I and 15-I carried the same protein-elongating p.
Pro1343Glnfs*49 variant. Although this variant occurs too distally
in the messenger RNA (mRNA) sequence to induce nonsense-
mediated decay, its pathogenicity is supported by the fact that
this variant, together with the previously described p.Glu1344-
Lysfs*49 variant,18 all occurred de novo in similarly affected
individuals. Although some of the patients in this series carried
additional rare variants, none of these are likely pathogenic.
Individual 1-I carries a 441-kb heterozygous interstitial micro-
duplication in 22q11.2 (hg19 (chr22:22,817,344–23,258,369) that
does not contain any disease-associated genes and was inherited
from his healthy father. Individual 5-I carried the recurrent 312-kb
interstitial duplication at 15q11.2 (hg19: 22,770,421–23,082,328)
that was inherited from her healthy mother. In a large study on
the effect of copy-number variants on cognition, 136 control
individuals carrying the 15q11.2 duplication performed to a similar
level as population controls on all tests of cognitive function.34 In
family 7, where both mildly affected siblings (individuals 7-I and 7-
II) inherited the NSD2 variant from their similarly affected mother,
we additionally found that individual 7-I carries a paternally
inherited 783-kb deletion at 9p13.3 (hg19: 35,487,232-36,270,255)
as well as the maternally inherited GABBR2 c.1656_1657delTT, p.
Cys553Hisfs*96 variant. Her father had learning disability and
depression. No overlapping deletion was present in the DECIPHER
database but, based on the gene content and on the family
history, a modulatory role of the 9p13.3 deletion on her
phenotype cannot be excluded. Except for one truncating variant
described in a large sequencing study on patients with
neurodevelopmental delay,35 all GABBR2 pathogenic variants
described until now in this gene are missense (source: HGMD
Professional, release 2020.2, see Web Resources). This, together
with the fact that her similarly affected brother (individual 7-II) did
not carry the p.Cys553Hisfs*96 GABBR2 variant, speaks against a
determining role on the phenotype. Individual 10-I carries a 38-kb
partial HUWE1 duplication in Xp11.2, which overlaps with a
recurrent polymorphic copy-number variant that does not affect
the expression of HUWE1 and thus should have no effect on
cognition.36
Our study leaves unanswered questions for future research,
such as the clarification of the full molecular mechanisms. This
may reveal potential targets for therapeutic interventions relevant
not only to patients with NSD2 deficiency, but also potentially
even to patients with obesity in general.
In conclusion, our data support the concept that NSD2 loss of
function is associated with a distinct phenotype that only partially
overlaps with WHS and constitutes a differential diagnosis to
Silver–Russell and similar syndromes. This phenotype is in line
with the distinct features described in the first patient with a small
deletion encompassing NSD2 by Rauch et al.8 This patient now at
age 26 years is 172 cm tall (-0.55 SDS), weighs 45–50 kg (ca. -2.5
SDS), and has a “small head.” Despite his normal eating behavior,
all attempts to gain weight have been unsuccessful. He has an IQ
in the lower-normal range, a calm and content personality, and
lives with his parents. As a reflection of the distinct facial gestalt
and the greatly different disease severity, especially concerning ID,
of NSD2 deficiency and contiguous gene deletions leading to
WHS, which may also be important for families’ and physicians'
perception of the patients’ prognosis, the NSD2-related disorder
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